DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2019 Results Earnings Conference Call March 24, 2020 8:00 AM ET Company Participants Rick Pauls - President, Chief Executive Officer Scott Kellen - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Thomas Flaten - Lake Street Capital Kyle Bauser - Dougherty Operator Ladies and gentlemen, thank you for standing by and welcome to the DiaMedica Therapeutics Inc. Q4 2019 results earnings conference call. At this time, all particip ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to __________________. Commission file number: 001-36291 ____________________ DIAMEDICA THERAPEUTICS INC. (Exact na ...

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2019 Earnings Conference Call November 14, 2019 8:00 AM ET CompanyParticipants Rick Pauls - President & CEO Scott Kellen - CFO Harry Alcorn - Chief Medical Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Thomas Flaten - Lake Street Capital Greg Bogdanski - Dougherty & Company Operator Good morning, ladies and gentlemen, and welcome to DiaMedica Therapeutics' Third Quarter 2019 Conference Call. An audio recording of the webcast will be avail ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to __________________. Commission File Number: 001-11038 ____________________ DIAMEDICA THERAPEUTICS INC. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to __________________. Commission File Number: 001-11038 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Br ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to __________________. Commission File Number: 001-11038 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) C ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to __________________. Commission file number: 001-36291 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Canada ...